Key points are not available for this paper at this time.
In routine clinical practice in Italy, patients with T2D treated with once-weekly semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, body weight and other outcomes.
Napoli et al. (Wed,) studied this question.